SELLAS Q1 net loss $9.6M; Phase 2 SLS009 100% response in ASXL1 AML; IDMC backs REGAL trial

SELLAS Life Sciences Group, Inc.

2024-Q1 EPS reported -$0.21

Net loss of $9.6M ($0.21/share) vs $11.1M ($0.47/share) in Q1 2023.
Cash and equivalents $18.4M at March 31, 2024; R&D expense $5.1M, G&A $4.5M.
IDMC recommends continue Phase 3 REGAL (GPS in AML) without modification; next review June 2024 of all 127 patients.
SLS009 Phase 2: 62% anti-leukemic activity all doses, 67% at 30mg BIW; 100% ORR in ASXL1 mutation patients at 30mg BIW; cohort expanding.
Phase 3 REGAL enrollment completed; provisional patent filed for SLS009 in ASXL1-mutated AML.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

SELLAS Life Sciences Group, Inc. reported the first quarter ended March 31, 2024 results: net income $9.6 million, EPS $0.21.

Period: the first quarter ended March 31, 2024
Net income: $9.6 million
EPS: $0.21
Result: reported results

Exact text from the filing

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

SELLAS Life Sciences Group, Inc. filing history →

Source: SEC EDGAR

accession 0001390478-24-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.